

Xanthus Names Robert L. Capizzi, M.D., F.A.C.P. Chief Medical Officer

CAMBRIDGE, Mass., May 4 /PRNewswire/ -- Xanthus Life Sciences today announced the appointment of Robert L. Capizzi, M.D. to the position of Senior Vice President and Chief Medical Officer. Dr. Capizzi is an internationally known figure in both academia and the life sciences industry with experience in pharmacologic research, clinical drug development and medical affairs. He has successfully led the development of several oncology drugs through U.S. and international regulatory agencies.

"Dr. Capizzi's product development experience and track record of bringing new oncology drugs to market provides Xanthus with the leadership to advance multiple exciting initiatives including our ongoing programs for acute myeloid leukemia and solid tumors," said Richard T. Dean, Ph.D., CEO of Xanthus. "We are proud to have Dr. Capizzi join our team as we endeavor to develop several products that address the need for improved medications to treat cancer patients."

Dr. Capizzi is a board certified medical oncologist whose career spans more than 30 years in clinical oncology and oncology drug development in academia and industry. He has achieved international recognition for his work in clinical pharmacology, cancer drug development, and clinical trials and his laboratory and clinical research has resulted in the development of novel therapies for various malignancies and curative therapies for acute leukemia. Dr. Capizzi's leadership extends beyond the laboratory and clinic into the international professional oncology community through service on the Boards of Directors of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), as a member and chair of the Food and Drug Administration's oncology drug advisory committee (ODAC) and various advisory boards for the National Institutes of Health (NIH) and the American Cancer Society.

"Through the development of its pipeline of anticancer drugs, Xanthus is poised to make important progress in the treatment of multiple cancer indications," said Dr. Capizzi. "I am excited about taking on this new role at Xanthus and the opportunity to contribute to the Company's success."

Before joining Xanthus, Dr. Capizzi served as Vice President, Medical Affairs at Novacea Inc., a privately-held biopharmaceutical company, where he focused on the clinical development needs of newly in-licensed drug candidates for the treatment of cancer. Dr. Capizzi was the Magee Professor and Chairman of the Department of Medicine at Jefferson Medical College in Philadelphia from 1996 to 2000. As Executive Vice President for Worldwide Research and Development at U.S. Bioscience, Inc., Dr. Capizzi led clinical development and regulatory teams that achieved marketing approval for two new drugs in the U.S., Canada, EU, and Latin America. Dr. Capizzi's educational background is from Temple University, Hahnemann University School of Medicine, both in Philadelphia, PA., and the Yale School of Medicine.

About Xanthus

Xanthus is an oncology drug development company. Xanthus' small molecule candidates are Xanafide, Symadex and Clomet which are advancing in clinical and preclinical development for multiple cancer indications. Each of these product candidates was in-licensed based on significant clinical and, or preclinical data supporting safety and activity. Xanthus also has proprietary technology to individualize patient dosing, which it believes may help improve the

performance of certain drugs in development, and facilitate the life cycle management of certain marketed products, without limiting patient populations or markets.

Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at <http://www.xanthus.com>.